Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors website and the webcast will be archived for replay within 24 hours.
Investors can listen via the company website at www.adaptivebiotech.com and should check the Investors section for the live link and replay.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ADPT declined 2.68%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ADPT was down 1.68% while peers showed mixed moves: AGIO +1.65%, TVTX +2.6%, TARS +0.49%, GLPG -0.06%, IDYA 0%, indicating stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim earnings | Positive | +15.9% | Preliminary Q4 and FY2025 revenue growth with strong MRD performance. |
| Dec 30 | Conference appearance | Neutral | -1.1% | Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 15 | Pfizer agreements | Positive | +1.6% | Two Pfizer collaborations with RA milestones potentially totaling about $890M. |
| Dec 09 | MRD fireside chat | Neutral | -0.6% | Jefferies fireside chat on MRD and clonoSEQ assay technology. |
| Nov 24 | ASH MRD data | Positive | +9.9% | clonoSEQ MRD featured in 89 abstracts and 36 orals at ASH 2025. |
Substantive developments such as strong preliminary FY2025 results and extensive clonoSEQ MRD data presentations have coincided with notable positive price reactions, suggesting the stock has historically responded well to clinically and financially meaningful news.
Over the last few months, Adaptive Biotechnologies reported strong preliminary Q4 and FY2025 results with revenue of about $72M for Q4 and $277M for FY2025, driving a 15.86% gain on Jan 12, 2026. A Pfizer licensing and target discovery deal highlighted up to about $890M in potential RA-related milestones. The clonoSEQ MRD assay featured in 89 abstracts, including 36 oral presentations at the 67th ASH meeting, which preceded a 9.94% move. Today’s earnings-date notice fits into this sequence of ongoing investor communications.
Market Pulse Summary
This announcement sets the timetable for Adaptive Biotechnologies’ full Q4 and FY2025 earnings release on February 5, 2026, following strong preliminary revenue growth reported on January 12, 2026. Recent milestones include extensive clonoSEQ MRD data at ASH and Pfizer licensing agreements with substantial potential milestones. Investors may focus on how final audited figures compare with the preliminary $277M FY2025 revenue and any updates on partnerships and MRD adoption.
AI-generated analysis. Not financial advice.
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) report Q4 and full year 2025 results?
What time is the Adaptive Biotechnologies (ADPT) earnings call on February 5, 2026?
How can investors listen to the Adaptive Biotechnologies (ADPT) webcast?
Will the Adaptive Biotechnologies (ADPT) webcast be available for replay?
Will Adaptive Biotechnologies (ADPT) management host a Q&A during the February 5, 2026 call?
Where can I find slides or a transcript for the Adaptive Biotechnologies (ADPT) February 5, 2026 presentation?
